TAVR ¿Cómo Seleccionar la Estrategia y la Técnica?

18_cohen_mauricio
Mauricio G. Cohen
2014-08-08

MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine

More articles by this author

Hay Lugar Aun Para los Inhibidores GPIIbIIIa?

Pedro Ureña Velásquez2014-08-08FACC FSCAI FACCPDirector Medicina Cardiovascular Asociada   

Thromboprophylaxis with antiplatelet agents in patients with mechanical aortic valves

Raúl García-Rinaldo2014-08-08MD, PhD, FACS Ponce School of Medicine, Ponce, PRMayaguez Medical Center, Mayaguez, PR

Evaluation and Management of Asymptomatic Aortic Stenosis

Augusto Pichard2014-08-08Director Innovation and Structural Heart Disease,  Vice Chair, Medstar Heart Institute, Medstar Washington Hospital Center. Professor of Medicine (Cardiology),Georgetown University Medical School.Washington, DC

Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy

Igor F. Palacios2014-08-08Director of Interventional CardiologyMassachusetts General HospitalProfessor of MedicineHarvard Medical School

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...